Page last updated: 2024-09-04

mdl 100240 and enalaprilat anhydrous

mdl 100240 has been researched along with enalaprilat anhydrous in 1 studies

Compound Research Comparison

Studies
(mdl 100240)
Trials
(mdl 100240)
Recent Studies (post-2010)
(mdl 100240)
Studies
(enalaprilat anhydrous)
Trials
(enalaprilat anhydrous)
Recent Studies (post-2010) (enalaprilat anhydrous)
219084610976

Protein Interaction Comparison

ProteinTaxonomymdl 100240 (IC50)enalaprilat anhydrous (IC50)
Angiotensin-converting enzymeMus musculus (house mouse)0.0115
Angiotensin-converting enzyme Homo sapiens (human)0.2405
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)0.0054
Type-2 angiotensin II receptorRattus norvegicus (Norway rat)0.0012
Angiotensin-converting enzymeRattus norvegicus (Norway rat)0.0036
Angiotensin-converting enzyme 2 Homo sapiens (human)0.0024

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bennett, T; Brunner-Ferber, F; Gardiner, SM; Kemp, PA1

Other Studies

1 other study(ies) available for mdl 100240 and enalaprilat anhydrous

ArticleYear
Comparative effects of the dual metallopeptidase inhibitor, MDL 100,240 and of enalaprilat on regional and on cardiac haemodynamics in conscious, hypertensive, transgenic ((mRen-2)27) rats.
    British journal of pharmacology, 1997, Volume: 122, Issue:8

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Benzazepines; Bradykinin; Enalaprilat; Hemodynamics; Hypertension; Male; Metalloendopeptidases; Protease Inhibitors; Pyridines; Rats

1997